Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19

This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).

Detalles Bibliográficos
Autores principales: van de Veerdonk, Frank L., Kouijzer, Ilse J. E., de Nooijer, Aline H., van der Hoeven, Hans G., Maas, Coen, Netea, Mihai G., Brüggemann, Roger J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426743/
https://www.ncbi.nlm.nih.gov/pubmed/32789513
http://dx.doi.org/10.1001/jamanetworkopen.2020.17708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426743/
https://www.ncbi.nlm.nih.gov/pubmed/32789513
http://dx.doi.org/10.1001/jamanetworkopen.2020.17708

Ejemplares similares